255 related articles for article (PubMed ID: 26078390)
1. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Zamagni E; Nanni C; Mancuso K; Tacchetti P; Pezzi A; Pantani L; Zannetti B; Rambaldi I; Brioli A; Rocchi S; Terragna C; Martello M; Marzocchi G; Borsi E; Rizzello I; Fanti S; Cavo M
Clin Cancer Res; 2015 Oct; 21(19):4384-90. PubMed ID: 26078390
[TBL] [Abstract][Full Text] [Related]
2. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
3. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X
Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
5. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
[TBL] [Abstract][Full Text] [Related]
6. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Baseline
Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
[TBL] [Abstract][Full Text] [Related]
8. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Haberkorn U; Strauss LG
Clin Nucl Med; 2009 Sep; 34(9):576-84. PubMed ID: 19692817
[TBL] [Abstract][Full Text] [Related]
9. Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma.
Li Y; Liu J; Huang B; Chen M; Diao X; Li J
Oncotarget; 2017 Apr; 8(15):25637-25649. PubMed ID: 27556189
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
11.
Jung SH; Kwon SY; Min JJ; Bom HS; Ahn SY; Jung SY; Lee SS; Park MR; Yang DH; Ahn JS; Kim HJ; Lee JJ
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):107-115. PubMed ID: 30187105
[TBL] [Abstract][Full Text] [Related]
12. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment
Abe Y; Narita K; Kobayashi H; Kitadate A; Miura D; Takeuchi M; O'uchi E; O'uchi T; Matsue K
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1325-1333. PubMed ID: 30687892
[TBL] [Abstract][Full Text] [Related]
14. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
16. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma.
Elliott BM; Peti S; Osman K; Scigliano E; Lee D; Isola L; Kostakoglu L
Eur J Haematol; 2011 Apr; 86(4):289-98. PubMed ID: 21198866
[TBL] [Abstract][Full Text] [Related]
17. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of
Tu H; He Y; Huang T; Choe S; Lan X; Duan X; Sattar H; Li C; Zhou F
Eur J Haematol; 2018 Feb; 100(2):189-197. PubMed ID: 29226428
[TBL] [Abstract][Full Text] [Related]
19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of Magnetic Resonance Imaging and [
Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]